Hardclav Tablet is a combination antibiotic formulation containing Amoxycillin 500 mg, Clavulanic Acid 125 mg, and Lactobacillus 60 million spores per tablet. Amoxycillin, a broad-spectrum penicillin antibiotic, exerts bactericidal activity by inhibiting bacterial cell wall synthesis, effectively treating a wide range of susceptible Gram-positive and Gram-negative infections. Clavulanic Acid, a beta-lactamase inhibitor, enhances the efficacy of Amoxycillin by preventing enzymatic degradation of the antibiotic, thereby overcoming resistance in beta-lactamase producing bacteria. The inclusion of Lactobacillus, a probiotic, helps maintain and restore normal intestinal flora during and after antibiotic therapy, reducing the risk of antibiotic-associated diarrhea and other gastrointestinal disturbances. Hardclav is indicated for the treatment of respiratory tract infections, urinary tract infections, skin and soft tissue infections, and other bacterial infections where beta-lactamase producing organisms are suspected. It should be used under medical supervision, with dosage adjusted according to the severity of infection and patient factors. Caution is advised in patients with a history of hypersensitivity to penicillins or cephalosporins. Common adverse effects may include gastrointestinal discomfort, diarrhea, and hypersensitivity reactions. Hardclav Tablet offers an effective therapeutic option combining antibacterial potency with probiotic support to improve patient outcomes during antibiotic therapy.